Oral manifestations of magnesium and vitamin D inadequacy
Adequate nutrition is essential for maintaining good oral health. Minerals such as
magnesium, calcium, and phosphorus found in the diet constitute the main structural …
magnesium, calcium, and phosphorus found in the diet constitute the main structural …
Intensive hemodialysis, mineral and bone disorder, and phosphate binder use
M Copland, P Komenda, ED Weinhandl… - American Journal of …, 2016 - Elsevier
Mineral and bone disorder is a common complication of end-stage renal disease. Notably,
hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries …
hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries …
Effect of tenapanor on serum phosphate in patients receiving hemodialysis
GA Block, DP Rosenbaum… - Journal of the …, 2017 - journals.lww.com
Hyperphosphatemia is common among patients with CKD stage 5D and is associated with
morbidity and mortality. Current guidelines recommend lowering serum phosphate …
morbidity and mortality. Current guidelines recommend lowering serum phosphate …
Replacing phosphorus-containing food additives with foods without additives reduces phosphatemia in end-stage renal disease patients: a randomized clinical trial
MLL de Fornasari, YA dos Santos Sens - Journal of Renal Nutrition, 2017 - Elsevier
Objective The purpose of the study was to verify the effects of replacing phosphorus-
containing food additives with foods without additives on phosphatemia in end-stage renal …
containing food additives with foods without additives on phosphatemia in end-stage renal …
Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles
F Locatelli, L Del Vecchio, L Violo… - Expert opinion on drug …, 2014 - Taylor & Francis
Introduction: Hyperphosphatemia is common in the late stages of chronic kidney disease
(CKD) and is associated with elevated parathormone levels, abnormal bone mineralization …
(CKD) and is associated with elevated parathormone levels, abnormal bone mineralization …
Osteoprotegerin is the strongest predictor for progression of arterial calcification in peritoneal dialysis patients
M Avila, C Mora, MC Prado, M Zavala… - American Journal of …, 2017 - karger.com
Background: Arterial calcification (AC) is frequent in patients with end stage renal disease
and is also considered a risk factor for later morbidity and mortality. However, long-term …
and is also considered a risk factor for later morbidity and mortality. However, long-term …
Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the …
K Yabuki, E Shiba, H Harada, K Uchihashi… - … -Research and Practice, 2016 - Elsevier
Lanthanum carbonate (LC) is one of the most potent phosphate binders currently used to
reduce serum phosphate levels in dialysis patients with end-stage renal disease (ESRD) …
reduce serum phosphate levels in dialysis patients with end-stage renal disease (ESRD) …
Is polypharmacy an increasing burden in chronic kidney disease? The German experience
K Parker, J Wong - Clinical Kidney Journal, 2019 - academic.oup.com
This is a commentary article describing the key findings of the German chronic kidney
disease (GCKD) study and how these relate to current practice. With the GCKD study …
disease (GCKD) study and how these relate to current practice. With the GCKD study …
Serum phosphorus and pill burden among hemodialysis patients prescribed sucroferric oxyhydroxide: one-year follow-up on a contemporary cohort
JB Kendrick, M Zhou, LH Ficociello… - … of Nephrology and …, 2022 - Taylor & Francis
Purpose In prior analyses of real-world cohorts of hemodialysis patients switched from one
phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated …
phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated …
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation–safety, efficacy, and patient adherence
MJ Lloret, C Ruiz-García, I DaSilva… - Patient preference …, 2013 - Taylor & Francis
Chronic kidney disease (CKD) is associated with very high mortality rates, mainly of
cardiovascular origin. The retention of phosphate (P) and increased fibroblast growth factor …
cardiovascular origin. The retention of phosphate (P) and increased fibroblast growth factor …